Bernard T, Johnson S A, Prentice A G, Jones L, Phillips M J, Newland A C
Department of Haematology, Royal London Hospital, Whitechapel, UK.
Leuk Lymphoma. 1994 Nov;15(5-6):481-5. doi: 10.3109/10428199409049751.
The management of low grade lymphoma, both de novo and relapsed disease, is a contentious area in which there has been little real progress in recent years. Regimens which increase the intensity of treatment may accelerate the response but are inevitably associated with greater toxicity. This cannot be justified in a disease whose median survival is between 4 and 10 years and where the median age at presentation is 57. We have assessed the response of 144 patients treated with a combination of mitoxantrone, chlorambucil and prednisolone in a heterogeneous group with lymphoma, both de novo and relapsed disease. In the subgroup with low grade relapsed/refractory disease our results suggest that this combination is clinically effective, low in toxicity and suitable for the outpatient management of this usually elderly patient population.
低度淋巴瘤（包括初发和复发疾病）的治疗是一个存在争议的领域，近年来几乎没有取得实质性进展。增加治疗强度的方案可能会加速缓解，但不可避免地会带来更大的毒性。对于一种中位生存期在4至10年且中位发病年龄为57岁的疾病来说，这样做是不合理的。我们评估了144例接受米托蒽醌、苯丁酸氮芥和泼尼松龙联合治疗的淋巴瘤患者的反应，这些患者包括初发和复发疾病的异质性群体。在低度复发/难治性疾病亚组中，我们的结果表明，这种联合治疗在临床上是有效的，毒性低，适合对这一通常为老年患者群体进行门诊管理。
